Business Context and Reporting Period
This Form 8-K Current Report was filed by Tempest Therapeutics, Inc. (TPST) on October 10, 2024, covering events occurring on October 7, 2024, and October 9, 2024. The filing details a strategic partnership for clinical trial supply and a modification to the company's shareholder rights plan.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Agreements
Roche Master Clinical Supply Agreement
- Counterparty: F. Hoffmann-La Roche Ltd. (Roche).
- Subject: Supply of atezolizumab (TECENTRIQ) for use in clinical studies involving Tempest's proprietary compound amezalpat (TPST-1120).
- Specific Commitment: A Clinical Supply Agreement (CSA) Supplement was executed for a planned Phase 3 trial in patients with unresectable or metastatic hepatocellular carcinoma.
- Cost: Roche will supply atezolizumab free of charge for the specified Phase 3 trial.
- Data Rights: Tempest retains sole ownership of all data, results, and reports generated from studies under the agreement.
- Termination: Either party may terminate the master agreement for convenience with 60 days' notice. Specific CSA Supplements may be terminated by Roche if no patients are treated within one year or if safety concerns arise.
Rights Agreement Amendment
- Action: Entered into Amendment No. 1 to the Rights Agreement dated October 10, 2023.
- Expiration Extension: The Final Expiration Date is extended to immediately following the 2025 Annual Meeting of Stockholders.
- Conditional Extension: If stockholders approve the Rights Plan at or prior to the 2025 meeting, the expiration extends to October 10, 2026.
- Approval: No stockholder approval is required for the Rights Agreement under current terms.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the timing of the Phase 3 pivotal study of amezalpat in combination with atezolizumab and Roche's future supply obligations. Management highlights several risks that could cause actual results to differ materially from expectations, including:
- Unexpected safety or efficacy data.
- Clinical trial site activation or enrollment rates lower than expected.
- Changes in competition or the regulatory environment.
- Unexpected litigation or disputes.
The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the specific terms and redacted confidential provisions of the Roche Master Clinical Supply Agreement in the upcoming Form 10-Q for the quarter ended September 30, 2024.
- Confirm the timeline for the initiation of the Phase 3 trial for amezalpat (TPST-1120) and the enrollment targets.
- Review the full text of Amendment No. 1 to the Rights Agreement (Exhibit 4.1) to understand any other potential modifications to the poison pill provisions.
- Monitor the company's cash burn rate and liquidity position, as this filing does not provide updated financial data.